{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T09:16:00Z","timestamp":1668676560216},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7958","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T22:07:55Z","timestamp":1497478075000},"page":"1531-1535","source":"Crossref","is-referenced-by-count":2,"title":["Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab"],"prefix":"10.2169","volume":"56","author":[{"given":"Akihito","family":"Tanaka","sequence":"first","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daijo","family":"Inaguma","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Ito","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kamegai","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Shimogushi","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hibiki","family":"Shinjo","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomi","family":"Koike","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Takeda","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278, 2005.","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Cholesterol Treatment Trialists' Collaboration; Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681, 2010.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"3","unstructured":"3. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63: 2889-2934, 2014."},{"key":"4","unstructured":"4. Teramoto T, Sasaki J, Ishibashi S, et al. Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version. J Atheroscler Thromb 20: 850-860, 2013."},{"key":"5","unstructured":"5. Matsuzaki M, Hiramori K, Imaizumi T, et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 40: 220-227, 2002."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 82: 1489-1495, 1998.","DOI":"10.1016\/S0002-9149(98)00692-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1500-1509, 2015.","DOI":"10.1056\/NEJMoa1500858"},{"key":"8","unstructured":"8. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385: 331-340, 2015."},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126: 2408-2417, 2012.","DOI":"10.1161\/CIRCULATIONAHA.112.144055"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 303: 893-896, 1991.","DOI":"10.1136\/bmj.303.6807.893"},{"key":"11","unstructured":"11. Farnier M. PCSK9: from discovery to therapeutic applications. Arch Cardiovasc Dis 107: 58-66, 2014."},{"key":"12","unstructured":"12. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32: 71-77, 2007."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ballard KD, Mah E, Guo Y, et al. Single low-density lipoprotein apheresis does not improve vascular endothelial function in chronically treated hypercholesterolemic patients. Int J Vasc Med 2016: 4613202, 2016.","DOI":"10.1155\/2016\/4613202"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Goldammer A, Wiltschnig S, Heinz G, et al. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. Metabolism 51: 976-980, 2002.","DOI":"10.1053\/meta.2002.34016"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95: 76-82, 1997.","DOI":"10.1161\/01.CIR.95.1.76"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Rubba P, Iannuzzi A, Postiglione A, et al. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation 81: 610-616, 1990.","DOI":"10.1161\/01.CIR.81.2.610"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Schuff-Werner P, Schutz E, Seyde WC, et al. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Eur J Clin Invest 19: 30-37, 1989.","DOI":"10.1111\/j.1365-2362.1989.tb00303.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/12\/56_56.7958\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T03:03:43Z","timestamp":1569467023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/12\/56_56.7958\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7958","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}